Role of Jo-1 in the Immunopathogenesis of the Anti-synthetase Syndrome

Current Rheumatology Reports

Volumn 17, Issue 9, 2015, Pages

  Ascherman, Dana P ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Adaptive immunity; Anti synthetase syndrome; Autoantibody; Histidyl tRNA synthetase (HRS = Jo 1); Innate immunity; Toll like receptor (TLR)

Indexed keywords

ALPHA INTERFERON; C REACTIVE PROTEIN; CHEMOKINE RECEPTOR CCR5; CXCL9 CHEMOKINE; GAMMA INTERFERON; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HISTIDINE TRANSFER RNA LIGASE; JO 1 ANTIBODY; MESSENGER RNA; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 9; ANTINUCLEAR ANTIBODY; JO-1 ANTIBODY;

ADAPTIVE IMMUNITY; ANTIBODY AFFINITY; ANTIBODY RESPONSE; ANTIBODY TITER; ANTIGEN PRESENTATION; ANTIGEN RECOGNITION; ANTIGEN SPECIFICITY; ANTISYNTHETASE SYNDROME; ASSESSMENT OF HUMANS; BINDING AFFINITY; CELL SURFACE; CELLULAR IMMUNITY; CLINICAL FEATURE; DISEASE ASSOCIATION; EXTRACELLULAR TRAP; GENE EXPRESSION REGULATION; HUMAN; HUMORAL IMMUNITY; IMMUNOPATHOGENESIS; INNATE IMMUNITY; INTERSTITIAL LUNG DISEASE; MYOSITIS; MYOSITIS DISEASE ACTIVITY ASSESSMENT TOOL; NONHUMAN; PHENOTYPE; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; UPREGULATION; AUTOIMMUNE DISEASE; BLOOD; IMMUNOLOGY; LUNG DISEASES, INTERSTITIAL; SYNDROME;

ADAPTIVE IMMUNITY; ANTIBODIES, ANTINUCLEAR; AUTOIMMUNE DISEASES; HISTIDINE-TRNA LIGASE; HUMANS; IMMUNITY, INNATE; LUNG DISEASES, INTERSTITIAL; MYOSITIS; SYNDROME;

EID: 84938903210     PISSN: 15233774     EISSN: 15346307     Source Type: Journal    
DOI: 10.1007/s11926-015-0532-1     Document Type: Review

References (34)

1. Greenberg SA. Inflammatory myopathies: disease mechanisms. Curr Opin Neurol. 2009;22:516–23.
2. Pignone A, Fiori G, Del Rosso A, Generini S, Matucci-Cerinic M. The pathogenesis of inflammatory muscle diseases: on the cutting edge among the environment, the genetic background, the immune response and the dysregulation of apoptosis. Autoimmun Rev. 2002;1:226–32.
3. Ascherman DP. The role of Jo-1 in the immunopathogenesis of polymyositis: current hypotheses. Curr Rheumatol Rep. 2003;5:425–30.
4. Betteridge ZE, Gunawardena H, McHugh NJ. Novel autoantibodies and clinical phenotypes in adult and juvenile myositis. Arthritis Res Ther. 2011;13:209.
5. Mammen AL. Autoimmune myopathies: autoantibodies, phenotypes and pathogenesis. Nat Rev Neurol. 2011;7:343–54.
6. Martin A, Shulman MJ, Tsui FW. Epitope studies indicate that histidyl-tRNA synthetase is a stimulating antigen in idiopathic myositis. FASEB J. 1995;9:1226–33.
7. Miller FW, Waite KA, Biswas T, Plotz PH. The role of an autoantigen, histidyl-tRNA synthetase, in the induction and maintenance of autoimmunity. Proc Natl Acad Sci U S A. 1990;87:9933–7. Through serial assessment of patient serum samples, the authors demonstrate spectratype broadening and affinity maturation of anti-Jo-1 antibody responses over time—both of which support antigen-driven humoral immune responses targeting Jo-1.
8. Mahler M, Miller FW, Fritzler MJ. Idiopathic inflammatory myopathies and the anti-synthetase syndrome: a comprehensive review. Autoimmun Rev. 2014;13:367–71.
9. Mozaffar T, Pestronk A. Myopathy with anti-Jo-1 antibodies: pathology in perimysium and neighbouring muscle fibres. J Neurol Neurosurg Psychiatry. 2000;68:472–8.
10. Aggarwal R, Cassidy E, Fertig N, Koontz DC, Lucas M, Ascherman DP, et al. Patients with non-Jo-1 anti-tRNA-synthetase autoantibodies have worse survival than Jo-1 positive patients. Ann Rheum Dis. 2014;73:227–32.
11. Bernstein RM, Morgan SH, Chapman J, Bunn CC, Mathews MB, Turner-Warwick M, et al. Anti-Jo-1 antibody: a marker for myositis with interstitial lung disease. Br Med J (Clin Res Ed). 1984;289:151–2.
12. Miller FW, Twitty SA, Biswas T, Plotz PH. Origin and regulation of a disease-specific autoantibody response. Antigenic epitopes, spectrotype stability, and isotype restriction of anti-Jo-1 autoantibodies. J Clin Invest. 1990;85:468–75.
13. Stone KB, Oddis CV, Fertig N, Katsumata Y, Lucas M, Vogt M, et al. Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy. Arthritis Rheum. 2007;56:3125–31. This manuscript demonstrates a correlation between anti-Jo-1 antibody titers and parameters of muscular as well as extra-muscular disease activity.
14. Yoshida S, Akizuki M, Mimori T, Yamagata H, Inada S, Homma M. The precipitating antibody to an acidic nuclear protein antigen, the Jo-1, in connective tissue diseases. A marker for a subset of polymyositis with interstitial pulmonary fibrosis. Arthritis Rheum. 1983;26:604–11.
15. Levine SM, Raben N, Xie D, Askin FB, Tuder R, Mullins M, et al. Novel conformation of histidyl-transfer RNA synthetase in the lung: the target tissue in Jo-1 autoantibody-associated myositis. Arthritis Rheum. 2007;56:2729–39.
16. Richards TJ, Eggebeen A, Gibson K, Yousem S, Fuhrman C, Gochuico BR, et al. Characterization and peripheral blood biomarker assessment of anti-Jo-1 antibody-positive interstitial lung disease. Arthritis Rheum. 2009;60:2183–92.
17. Krystufkova O, Vallerskog T, Helmers SB, Mann H, Putova I, Belacek J, et al. Increased serum levels of B cell activating factor (BAFF) in subsets of patients with idiopathic inflammatory myopathies. Ann Rheum Dis. 2009;68:836–43.
18. Barbasso Helmers S, Englund P, Engstrom M, Ahlin E, Fathi M, Janciauskiene S, et al. Sera from anti-Jo-1-positive patients with polymyositis and interstitial lung disease induce expression of intercellular adhesion molecule 1 in human lung endothelial cells. Arthritis Rheum. 2009;60:2524–30.
19. Ascherman DP, Oriss TB, Oddis CV, Wright TM. Critical requirement for professional APCs in eliciting T cell responses to novel fragments of histidyl-tRNA synthetase (Jo-1) in Jo-1 antibody-positive polymyositis. J Immunol. 2002;169:7127–34.
20. Blechynden LM, Lawson MA, Tabarias H, Garlepp MJ, Sherman J, Raben N, et al. Myositis induced by naked DNA immunization with the gene for histidyl-tRNA synthetase. Hum Gene Ther. 1997;8:1469–80. This work shows that intramuscular immunization with a cDNA construct expressing human histidyl-tRNA synthetase induces low level anti-Jo-1 antibody responses as well as localized muscle inflammation; at the same time, these studies highlight some of the key variables distinguishing immune responses to protein/adjuvant combinations from those triggered by DNA immunization.
21. Katsumata Y, Ridgway WM, Oriss T, Gu X, Chin D, Wu Y, et al. Species-specific immune responses generated by histidyl-tRNA synthetase immunization are associated with muscle and lung inflammation. J Autoimmun. 2007;29:174–86. Based on an antigen/adjuvant immunization strategy, this work illustrates the importance of species-specific immune responses against HRS in determining phenotypic expression of myositis as well as inflammatory lung disease characteristic of the anti-synthetase syndrome.
22. Wakasugi K, Schimmel P. Two distinct cytokines released from a human aminoacyl-tRNA synthetase. Science. 1999;284:147–51. This paradigm-shifting work demonstrated that tyrosyl-tRNA synthetase possesses non-enzymatic, cytokine-like properties.
23. Howard OM, Dong HF, Yang D, Raben N, Nagaraju K, Rosen A, et al. Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med. 2002;196:781–91. Consistent with previous observations pertaining to tyrosyl-tRNA synthetase, these studies detail chemokine-like properties of two additional tRNA synthetases targeted in the anti-synthetase syndrome—histidyl-tRNA synthetase (HRS = Jo-1) and asparaginyl-tRNA synthetase (ARS = KS).
24. Zhou JJ, Wang F, Xu Z, Lo WS, Lau CF, Chiang KP, et al. Secreted histidyl-tRNA synthetase splice variants elaborate major epitopes for autoantibodies in inflammatory myositis. J Biol Chem. 2014;289:19269–75.
25. Zhang S, Shu X, Tian X, Chen F, Lu X, Wang G. Enhanced formation and impaired degradation of neutrophil extracellular traps in dermatomyositis and polymyositis: a potential contributor to interstitial lung disease complications. Clin Exp Immunol. 2014;177:134–41.
26. Eloranta ML, Barbasso Helmers S, Ulfgren AK, Ronnblom L, Alm GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum. 2007;56:3112–24. These in vitro studies provide a plausible mechanism linking Jo-1/anti-Jo-1 immune complex formation to activation of endosomal toll-like receptors and subsequent elaboration of Type I interferons involved in innate immune signaling pathways.
27. Sciorati C, Monno A, Ascherman DP, Seletti E, Manfredi AA, Rovere-Querini P. Required role of apoptotic myogenic precursors and toll-like receptor stimulation for the establishment of autoimmune myositis in experimental murine models. Arthritis Rheumatol. 2015;67:809–22.
28. Soejima M, Kang EH, Gu X, Katsumata Y, Clemens PR, Ascherman DP. Role of innate immunity in a murine model of histidyl-transfer RNA synthetase (Jo-1)-mediated myositis. Arthritis Rheum. 2011;63:479–87. This manuscript details the development of an alternative, antigen (HRS)-induced model of myositis (based on intramuscular immunization with recombinant HRS in the absence of additional exogenous adjuvant) that features HRS-mediated activation of innate immune responses.
29. Fernandez I, Harlow L, Zang Y, Liu-Bryan R, Ridgway WM, Clemens PR, et al. Functional redundancy of MyD88-dependent signaling pathways in a murine model of histidyl-transfer RNA synthetase-induced myositis. J Immunol. 2013;191:1865–72. As a follow up to reference 28, this work defines the central role of MyD88-dependent signaling pathways in the intramuscular immunization model of HRS-induced myositis and highlights the unique capacity of HRS to interact with various endogenous/exogenous ligands of MyD88-dependent toll-like receptors.
30. Grundtman C, Bruton J, Yamada T, Ostberg T, Pisetsky DS, Harris HE, et al. Effects of HMGB1 on in vitro responses of isolated muscle fibers and functional aspects in skeletal muscles of idiopathic inflammatory myopathies. FASEB J. 2010;24:570–8.
31. Zong M, Bruton JD, Grundtman C, Yang H, Li JH, Alexanderson H, Palmblad K, Andersson U, Harris HE, Lundberg IE, et al.: TLR4 as receptor for HMGB1 induced muscle dysfunction in myositis. Ann Rheum Dis 2012.
32. Brunn A, Zornbach K, Hans VH, Haupt WF, Deckert M. Toll-like receptors promote inflammation in idiopathic inflammatory myopathies. J Neuropathol Exp Neurol. 2012;71:855–67. This analysis provides compelling evidence that TLR-mediated signaling pathways are operative in muscle tissue derived from myositis patients.
33. Kim GT, Cho ML, Park YE, Yoo WH, Kim JH, Oh HJ, et al. Expression of TLR2, TLR4, and TLR9 in dermatomyositis and polymyositis. Clin Rheumatol. 2010;29:273–9.
34. Chinoy H, Li CK, Platt H, Fertig N, Varsani H, Gunawardena H, et al. Genetic association study of NF-kappaB genes in UK Caucasian adult and juvenile onset idiopathic inflammatory myopathy. Rheumatology (Oxford). 2012;51:794–9.